Bristol Myers Squibb (BMS) has been facing tremendous activity on multiple fronts. The company's CEO, Chris Boerner, has spoken about reshaping the company culture to deal with the looming patent cliff challenge. The company gave updates on the Cobenfy trial for Alzheimer's psychosis, which is delayed due to site irregularities. Despite this setback, the company's stock value has been holding strong, even gaining after the announcement of the delay. In the advancements of its scientific research, BMS has secured the fifth US approval for its CAR T cell therapy, Breyanzi. This approval by the FDA marks Breyanzi as the first and only treatment for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL). There have also been several shifts in company stock holdings, but clear trends are hard to identify as both buying and selling moves have occured. BMS also faces a hefty $6.7 billion lawsuit over a delayed cancer drug. Furthermore, the company has continued with its ADEPT-2 Phase 3 study of Cobenfy in Alzheimer's disease, while entering a collaboration for AI-enabled drug discovery.
Bristol-Myers Squibb News Analytics from Wed, 14 May 2025 07:00:00 GMT to Sat, 06 Dec 2025 19:57:11 GMT - Rating 4 - Innovation 7 - Information 9 - Rumor -5
